SYNCOMFSyncom Formulations (India) Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.1 this quarter.
Momentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹142 Cr | ₹27 Cr | 21.37% | 18.75% | ₹0.28 | 88.9x |
| Q1 FY2027 | ₹126 Cr | ₹25 Cr | 19.65% | 19.79% | ₹0.26 | 135.4x |
| Q4 FY2026 | ₹135 Cr | ₹25 Cr | 14.42% | 18.59% | ₹0.27 | 92.1x |
| Q3 FY2026 | ₹115 Cr | ₹19 Cr | 17.30% | 16.46% | ₹0.23 | 101.2x |
| Q2 FY2026 | ₹121 Cr | ₹17 Cr | 14.30% | 13.87% | ₹0.18 | 90.4x |
| Q1 FY2026 | ₹117 Cr | ₹16 Cr | 12.38% | 13.49% | ₹0.21 | 89.0x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.